trigonelline (Mole and Turner 1974; Salemink et al. 1966; 
Schulze and Frankfurt 1894); N-(p-hydroxy-B-phenethyl)-p- 
hydroxy-trans-cinnamide (Slatkin et al. 1971); and L{+)-isoleu- 
cine betaine (Lousberg and Salemink 1973). 
Spiro-compounds. Recently, several spiro-compounds have 
been isolated from Cannabis sativa of various geographical 
origins, such as cannabispirone (El-Feraly et al. 1977; Bercht et 
al. 1976b); dehydrocannabispiran (cannabispirenone) (Bercht et 
al. 1976b); cannabispiranol (B-cannabispiranol) (Boeren et al. 
1977; Crombie et al. 1978); cannabispiradienone (Crombie et al. 
1979) and acetyl cannabispiranol (Shoyama and Nishioka 1978). 
Dihydrostilbenes. A group of substituted dihydrostilbenes of 
biogenetic interest has been isolated from Cannabis sativa, 
including cannabiprene, 3,3’-dihydroxy-4,5’-dimethoxybibenzyl 
and 3,4’-dihydroxy-5-methoxybibenzyl (Crombie and Crombie 
1978) and  3’,4’-dihydroxy-5,5’-dimethoxy-3-(3-methy] but-2- 
enyl)-bibenzyl (Kettenes-van den Bosch et al. 1978). 
Phenanthrenes. A single example of a phenanthrene deriva- 
tive has been isolated from Cannabis sativa, which has been 
named cannabidihydrophenanthrene (Crombie et al. 1979). 
Coumarones. Two coumarone derivatives, cannabicoumaro- 
none and cannabicoumarononic acid (Grote and Spiteller |978b) 
have recently been isolated from Cannabis sativa. 
Current information suggests that Cannabis exists as three 
main phenotypes (Fetterman et al. 1971). Type I contains 
usually 0.3% of A’-THC, and these plants most frequently 
originate from countries south of latitude 30° N. Type I contains 
also low amounts of cannabidiol (0.5%). Type II Cannabis 
likewise usually has a high A’-THC content (0.3%), but more 
than 0.5% cannabidiol. Type II] Cannabis in general has 0.3% 
A’-THC and 0.5% cannabidiol. Both types II and III appear to 
originate in countries north of latitude 30° N. To date, no one 
has correlated cannabinoid content with definite taxonomic 
concepts. 
d. PHARMACOLOGY OF CANNABIS. The public uproar surrounding 
Cannabis and its constituents represents a classic example of 
legal hindrance to drug development. Societal, political factors 
and irresponsible publicity have compounded the problem. 
139 
